Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of CP/CPPS

NCT01391338 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01391338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01391338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of CP/CPPS
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
February 28, 2013
Enrollment
239 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

chronic abacterial prostatitis, chronic pelvic pain syndrome